JP2016504325A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504325A5 JP2016504325A5 JP2015548130A JP2015548130A JP2016504325A5 JP 2016504325 A5 JP2016504325 A5 JP 2016504325A5 JP 2015548130 A JP2015548130 A JP 2015548130A JP 2015548130 A JP2015548130 A JP 2015548130A JP 2016504325 A5 JP2016504325 A5 JP 2016504325A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound according
- composition
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 239000000203 mixture Substances 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000000304 alkynyl group Chemical group 0.000 claims 11
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- -1 cycloalkynyl Chemical group 0.000 claims 9
- 230000027756 respiratory electron transport chain Effects 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 230000005865 ionizing radiation Effects 0.000 claims 5
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010049811 Extraskeletal ossification Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 208000034970 Heterotopic Ossification Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000002154 Pterygium Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000014070 Vestibular schwannoma Diseases 0.000 claims 1
- 208000004064 acoustic neuroma Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011096 spinal cancer Diseases 0.000 claims 1
- 208000014618 spinal cord cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261797983P | 2012-12-20 | 2012-12-20 | |
| US61/797,983 | 2012-12-20 | ||
| PCT/CA2013/051005 WO2014094178A1 (en) | 2012-12-20 | 2013-12-20 | Radiosensitizer compounds for use in combination with radiation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504325A JP2016504325A (ja) | 2016-02-12 |
| JP2016504325A5 true JP2016504325A5 (cg-RX-API-DMAC10.html) | 2017-02-09 |
| JP6321673B2 JP6321673B2 (ja) | 2018-05-09 |
Family
ID=50977492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548130A Expired - Fee Related JP6321673B2 (ja) | 2012-12-20 | 2013-12-20 | 放射線と組み合わせて使用するための放射線増感剤化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9655965B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2935215B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6321673B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102278760B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN105164107B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2013362757B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112015014855A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2895526C (cg-RX-API-DMAC10.html) |
| MX (1) | MX2015008010A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2014094178A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015051458A1 (en) | 2013-10-08 | 2015-04-16 | Lu qing-bin | Non-platimun-based anti-cancer compounds for use in targeted chemotherapy |
| AU2016242118B2 (en) * | 2015-04-02 | 2021-07-08 | Proximagen, Llc | Novel therapies for cancer |
| CN106045932B (zh) * | 2016-06-06 | 2018-05-15 | 浙江省肿瘤医院 | 一种具有放射增敏作用的化合物及其应用 |
| JP6955243B2 (ja) * | 2017-02-24 | 2021-10-27 | 学校法人北里研究所 | ネクローシスの検出キット及びその使用 |
| KR102263216B1 (ko) * | 2018-05-30 | 2021-06-14 | (주)파로스아이바이오 | 2,3,5-치환된 싸이오펜 화합물의 방사선 치료 증진 용도 |
| WO2021224186A1 (en) * | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
| CN114478524A (zh) * | 2022-03-15 | 2022-05-13 | 江苏省肿瘤医院 | 1,8-萘啶类化合物及其应用 |
| CN114560799A (zh) * | 2022-03-15 | 2022-05-31 | 江苏省肿瘤医院 | 腈基取代苯基类化合物及其应用 |
| CN120501862B (zh) * | 2025-07-18 | 2025-10-10 | 四川大学华西医院 | 一种能够放射增敏和防护放射性损伤的双效化合物、包含其的组合物及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5011451B1 (cg-RX-API-DMAC10.html) * | 1969-05-05 | 1975-05-01 | ||
| GB1363735A (en) * | 1970-10-23 | 1974-08-14 | Hoechst Ag | Process for the manufacture of benzimidazolones |
| US3822261A (en) * | 1972-10-30 | 1974-07-02 | Dow Chemical Co | 5,6-dihalo-2-fluoroalkyl-1h-imidazo(4,5-b)pyrazines |
| PH15791A (en) * | 1978-10-20 | 1983-03-25 | Lilly Co Eli | Pharmaceutical composition containing 3,4-dihydro-3-oxoquinoxalines |
| US4210647A (en) * | 1979-06-18 | 1980-07-01 | Eli Lilly And Company | Antiviral combinations |
| JPS597175A (ja) * | 1982-07-01 | 1984-01-14 | メルク・エンド・カムパニ−・インコ−ポレ−テツド | 放射線治療用添加剤として有用な、クロロニトロアミノピラジン及びアルキルアミノピラジンのアミノとアミド誘導体 |
| GB8722488D0 (en) * | 1987-09-24 | 1987-10-28 | Fujisawa Pharmaceutical Co | Imidazopyridine compound |
| AU672617B2 (en) * | 1992-06-22 | 1996-10-10 | Regents Of The University Of California, The | Glycine receptor antagonists and the use thereof |
| IL112235A (en) * | 1994-01-03 | 2000-06-29 | Acea Pharm Inc | 1,4-dihydro-pyrido¬2,3-b¾pyrazine-2,3-dione (5 or 8) oxide derivatives and pharmaceutical compositions containing them |
| US5753687A (en) * | 1995-06-19 | 1998-05-19 | Ontogen Corporation | Modulators of proteins with phosphotryrosine recognition units |
| EP1254116A4 (en) * | 2000-01-24 | 2003-04-23 | Merck & Co Inc | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS |
| US6538010B1 (en) * | 2000-11-08 | 2003-03-25 | Research Triangle Institute | Compounds and methods for promoting smoking cessation |
| GB0428082D0 (en) * | 2004-12-22 | 2005-01-26 | Welcome Trust The Ltd | Therapeutic compounds |
| TWI371447B (en) | 2005-04-01 | 2012-09-01 | Taiho Pharmaceutical Co Ltd | Radiotherapy enhancer having a pyridine derivative as an active ingredient |
| ZA200708367B (en) * | 2005-04-01 | 2009-04-29 | Taiho Pharmaceutical Co Ltd | Potentiator for radiation therapy comprising pyridine derivative as active ingredient |
| EP2049481A2 (en) * | 2006-08-09 | 2009-04-22 | SmithKline Beecham Corporation | Novel compounds as antagonists or inverse agonists for opioid receptors |
| US8088767B2 (en) * | 2006-09-28 | 2012-01-03 | Exelixis, Inc. | JAK-2 modulators and methods of use |
| CA2672940A1 (en) | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
| CN102264721B (zh) * | 2008-11-10 | 2015-12-09 | 沃泰克斯药物股份有限公司 | 用作atr激酶抑制剂的化合物 |
| US20120156311A1 (en) | 2009-09-01 | 2012-06-21 | Lu qing-bin | Combination therapy for cancer comprising a platinum-based antineoplastic agent and a biocompatible electron donor |
| US8962631B2 (en) * | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| GB201017345D0 (en) * | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
-
2013
- 2013-12-20 US US14/654,165 patent/US9655965B2/en not_active Expired - Fee Related
- 2013-12-20 JP JP2015548130A patent/JP6321673B2/ja not_active Expired - Fee Related
- 2013-12-20 AU AU2013362757A patent/AU2013362757B2/en not_active Ceased
- 2013-12-20 WO PCT/CA2013/051005 patent/WO2014094178A1/en not_active Ceased
- 2013-12-20 KR KR1020157019682A patent/KR102278760B1/ko not_active Expired - Fee Related
- 2013-12-20 EP EP13865418.1A patent/EP2935215B1/en active Active
- 2013-12-20 BR BR112015014855A patent/BR112015014855A2/pt not_active Application Discontinuation
- 2013-12-20 CN CN201380073147.7A patent/CN105164107B/zh not_active Expired - Fee Related
- 2013-12-20 MX MX2015008010A patent/MX2015008010A/es unknown
- 2013-12-20 CA CA2895526A patent/CA2895526C/en active Active